Adoria SIA
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Adoria SIA in Riga, clinical research in cardiovascular medicine focuses on people with atherosclerotic cardiovascular disease and related risk conditions such as hypercholesterolemia. These studies are designed to assess whether new treatments can better lower LDL cholesterol and help prevent serious heart and blood vessel events.
- Reducing LDL-C to help patients reach individualized cholesterol targets
- Preventing major cardiovascular events such as heart attack, stroke, and cardiovascular death
- Evaluating therapies for ASCVD and inflammation-related cardiovascular risk
Overall, this area of research is centered on improving long-term protection for patients with established vascular disease and broader cardiometabolic risk.
Skin and Connective Tissue Diseases
The site also conducts studies in dermatology, with a strong focus on moderate to severe plaque psoriasis. These trials are exploring whether newer oral treatments can improve symptom control, support long-term use, and offer better results than existing options.
- Testing new therapies for plaque psoriasis
- Comparing treatment effectiveness against established medicines
- Assessing safety, tolerability, and overall disease control in chronic skin inflammation
Research in this therapeutic area aims to give patients more effective choices for managing a persistent and often burdensome skin condition.
Cardiometabolic Inflammation and Kidney-Related Risk
Another important research theme at this hospital/clinic is the overlap between cardiovascular disease, chronic kidney disease, and systemic inflammation. These trials are evaluating whether targeting inflammation can reduce the risk of major cardiovascular complications in people with complex, high-risk disease profiles.
- Studying inflammation-driven risk in patients with ASCVD and CKD
- Testing approaches intended to lower the chance of major adverse cardiovascular events
- Exploring treatment strategies for patients with multiple linked chronic conditions
This line of research reflects a broader effort to improve outcomes in patients whose heart disease is complicated by kidney disease and ongoing inflammatory activity.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Adoria SIA
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Zasocitinib in Moderate-to-Severe Plaque Psoriasis: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study | Takeda Development Center Americas Inc. | Phase III | Not Recruiting | May 2024 | Oct 2025 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 3 | Unknown | 2024-05-07 | 2025-09-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.